AstraZeneca’s Covid drug loses authorization in Brazil due to lack of efficacy

Rate this post

On Tuesday (Mar. 7), Brazil’s National Health Regulator (Anvisa) temporarily suspended the authorization for emergency use of the drug Evusheld, produced by the pharmaceutical giant AstraZeneca to treat the disease early.

According to Anvisa, the drug will be suspended “until data proving its efficacy against the variants of Sars-CoV-2 circulating in the country are presented.”

The drug received emergency approval from Anvisa in December 2022. According to the agency, the substance could be used in adults and children as young as 12.

Last month, the U.S. regulatory agency, Food and Drug Administration (FDA), considered AstraZeneca’s . . .

To read the full NEWS and much more, Subscribe to our Premium Membership Plan. Already Subscribed?

Source link

Leave a Comment